Sponsor Overview
Explore verified public information about D3 Bio (Wuxi) Co., Ltd's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“D3 Bio is willing to provide our following investigational drugs in compliance with FDA’s Expanded Access (Compassionate Use) to investigational drugs regulations: - D3S-001, for treatment of eligible patients with KRAS G12C-mutated advanced colorectal cancer and non-small cell lung cancer. - D3L-001, for treatment of eligible patients with locally advanced or metastatic HER2-positive breast cancer.”
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.